Lv1
36 积分 2023-03-23 加入
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
2个月前
已完结
Flow cytometric characterization of lymphocyte subpopulations in the cynomolgus monkey (Macaca fascicularis)
4个月前
已完结
Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence
4个月前
已完结
A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)
8个月前
已完结
In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery
8个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
8个月前
已完结
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
8个月前
已完结
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
9个月前
已关闭
皖公网安备34019202002308